Next Article in Journal
Differentiation of Heterogeneous Mouse Liver from HCC by Hyperpolarized 13C Magnetic Resonance
Previous Article in Journal
Organic Molecules: Is It Possible to Distinguish Aromatics from Aliphatics Collected by Space Missions in High-Speed Impacts?
Open AccessCommentaryPost Publication Peer ReviewVersion 1, Original

Advancing Therapies for Cancer—From Mustard Gas to CAR T (Version 1, Original)

1
Department of Bioengineering, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA
2
Cell and Molecular Biology Program, Colorado State University, Fort Collins, CO 80523, USA
3
Department of Clinical Sciences, Colorado State University, Fort Collins, CO 80523, USA
4
Epidemiology Section, Colorado School of Public Health, Colorado State University, Fort Collins, CO 80523, USA
*
Author to whom correspondence should be addressed.
Received: 27 May 2020 / Accepted: 5 June 2020 / Published: 10 June 2020
Peer review status: 1st round review Read review reports Apply as reviewer

Reviewer 1 Helmout Modjtahedi Faculty of Science, Engineering and Computing, Penrhyn Road,Kingston upon Thames,Surrey KT1 2EE, United Kingdom Reviewer 2 Radosław Zagożdżon Department of Immunology, Center of Biostructure Research, Medical University of Warsaw, Banacha 1A, 02-097 Warsaw, Poland Reviewer 3
Version 1
Original
Approved Approved with revisions Reviewer inviting
The development of targeted therapeutics for cancer continues to receive intense research attention as laboratories and pharmaceutical companies seek to develop drugs and technologies that improve treatment efficacy and mitigate harmful side effects. In the aftermath of World War I, it was discovered that mustard gas destroys rapidly dividing cells and could be used to treat cancer. Since then, chemotherapy has remained a predominant treatment for cancer; however, the destruction of dividing cells throughout the body yields devastating side effects including off-target damage of the digestive tract, bone marrow, skin, and reproductive tract. Furthermore, the high mutation rate of cancerous cells often renders chemotherapy ineffective long-term. Therapies with improved specificity, localization, and efficacy are redefining cancer treatment. Herein, we define and summarize the principal advancements in targeted cancer treatment and briefly comment on the march towards personalized medicine in the treatment of human cancer. View Full-Text
Keywords: small molecule inhibitor; personalized medicine; precision medicine; oncology; targeted therapy; drug delivery; drug screening; chemotherapy small molecule inhibitor; personalized medicine; precision medicine; oncology; targeted therapy; drug delivery; drug screening; chemotherapy
Show Figures

Figure 1

MDPI and ACS Style

Jarrell, D.K.; Drake, S.; Brown, M.A. Advancing Therapies for Cancer—From Mustard Gas to CAR T. Sci 2020, 2, 42.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1

Reviewer 1

Sent on 30 Jun 2020 by Helmout Modjtahedi | Approved
Faculty of Science, Engineering and Computing, Penrhyn Road,Kingston upon Thames,Surrey KT1 2EE, United Kingdom

This is a very well written commentary highlighting "Key Advances in Cancer Therapeutics".

Perhaps, this commentary will be strengthened if the authors could also mention targeted therapy using the checkpoint inhibitors and by including a recent review article as a supporting reference for this approach.

Reviewer 2

Sent on 30 Jun 2020 by Radosław Zagożdżon | Approved with revisions
Department of Immunology, Center of Biostructure Research, Medical University of Warsaw, Banacha 1A, 02-097 Warsaw, Poland

It would be worth mentioning that targeting the cancer-associated immune checkpoints by monoclonal antibodies has been one of the most important advances in strategies for re-shaping the specific immune response against cancer. 

Back to TopTop